Dutch biotech company Laigo Bio has successfully closed a €17 million seed funding round to advance its innovative drug discovery platform, SureTACs. The round, which exceeded its target, was led by Kurma Partners and now includes Biovance Capital as a co-lead investor. This funding marks a significant step forward for Laigo Bio, which is focused on tackling one of the most challenging areas in pharmaceutical research: membrane proteins.
Revolutionary Approach to Drug Discovery
Unlike traditional drug development methods that rely on blocking proteins, Laigo Bio’s SureTACs platform takes a novel approach by engineering membrane proteins out of existence. This strategy targets proteins that have long been considered 'undruggable' due to their complex structures and lack of suitable binding sites for conventional therapeutics. By using targeted protein degradation techniques, SureTACs aim to eliminate disease-causing proteins entirely, offering a more precise and potentially more effective treatment approach.
Industry Impact and Future Prospects
The investment underscores growing confidence in Laigo Bio’s technology and its potential to transform the landscape of drug discovery. With approximately 60% of all known drug targets being membrane proteins, the company’s approach could unlock new treatments for a wide range of diseases, including cancer, neurodegenerative disorders, and rare genetic conditions. The funding will be used to expand the platform’s research capabilities, enhance its pipeline, and prepare for future clinical trials.
As the biotech industry continues to evolve, companies like Laigo Bio are pushing the boundaries of what’s possible in therapeutic development. Their innovative approach not only addresses long-standing challenges in drug discovery but also opens up new possibilities for treating previously untreatable conditions.
